Cell & Gene
Commercialization of CAR-T therapy in New Zealand: clinical insights & scalable manufacturing
12 Aug 2025 | Online
A pioneering CAR-T program is redefining treatment for relapsed/refractory B-cell non-Hodgkin lymphoma. Join leading scientists as they share exclusive data and lessons learned from New Zealand’s first CD19-specific CAR-T cell therapy program.